Anti-CD8 Antibody [YCATE55.9] (FITC) (A282025)

Anti-CD8 Antibody [YCATE55.9] (FITC)

Rat monoclonal [YCATE55.9] antibody to CD8 (FITC).

This antibody recognises a rat cell line transfected with cDNA for canine CD8a and blocks MHC class I dependant T-cell responses in vitro and in vivo.Rat anti Dog CD8, clone YCATE55.9 has been shown to deplete circulating CD8+ T cells when administered to dogs in vivo. Reduced levels of circulating CD8+ T cells has been associated with decreased survival times for dogs with osteosarcoma.

Flow Cytometry: Neat - 1:5, Use 10µl of the suggested working dilution to label 10⁶ cells in 100µl

Canine

Canine CD8 alpha chimaeric human IgG1 Fc fusion protein.

Rat

Monoclonal

YCATE55.9

Protein G affinity chromatography of tissue culture supernatant.

100 µg/ml

Liquid

Supplied in Phosphate Buffered Saline with 1% BSA and 0.09% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Rat anti Dog CD8 antibody, clone YCATE55.9 was clustered as Canine CD8 in the First Canine Leukocyte Antigen Workshop (Cobbold et al. 1994). YCATE55.9 reacts with a rat cell line transfected with cDNA for canine CD8a (Gorman et al. 1994) and blocks MHC class I dependant T-cell responses in vitro and in vivo.Rat anti Dog CD8, clone YCATE55.9 has been shown to deplete circulating CD8+ T cells when administered to dogs in vivo. (Watson et al. 1993) Reduced levels of circulating CD8+ T cells has been associated with decreased survival times for dogs with osteosarcoma (Biller et al. 2010).

Activation B7-1 antigen, B7, BB1, CD28LG, CD28LG1, CD80, CTLA-4 counter-receptor B7.1, LAB7, T-lymphocyte activation antigen CD80

This product is for research use only. It is not intended for diagnostic or therapeutic use.